Amarin Corp Plc (AMRN)

[Biobillionair]

That’s key:

True but the real damage is being done at the insurance level, whether Hikma launch is slow or not. Much of the progress AMRN made moving Vascepa up the tiers is being lost.

And this is why Amarin must drop pricing to no profit levels in US and just seek damages that could be as high or higher that Hikma market cap.

I’m certain 8 agrees.

BB